全文获取类型
收费全文 | 9883篇 |
免费 | 501篇 |
国内免费 | 99篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 189篇 |
妇产科学 | 84篇 |
基础医学 | 1020篇 |
口腔科学 | 341篇 |
临床医学 | 583篇 |
内科学 | 2876篇 |
皮肤病学 | 64篇 |
神经病学 | 824篇 |
特种医学 | 316篇 |
外科学 | 1907篇 |
综合类 | 38篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 249篇 |
眼科学 | 159篇 |
药学 | 559篇 |
中国医学 | 27篇 |
肿瘤学 | 1164篇 |
出版年
2023年 | 59篇 |
2022年 | 116篇 |
2021年 | 230篇 |
2020年 | 134篇 |
2019年 | 181篇 |
2018年 | 238篇 |
2017年 | 188篇 |
2016年 | 245篇 |
2015年 | 243篇 |
2014年 | 359篇 |
2013年 | 401篇 |
2012年 | 622篇 |
2011年 | 706篇 |
2010年 | 460篇 |
2009年 | 403篇 |
2008年 | 661篇 |
2007年 | 676篇 |
2006年 | 618篇 |
2005年 | 665篇 |
2004年 | 643篇 |
2003年 | 619篇 |
2002年 | 615篇 |
2001年 | 117篇 |
2000年 | 100篇 |
1999年 | 125篇 |
1998年 | 161篇 |
1997年 | 112篇 |
1996年 | 89篇 |
1995年 | 82篇 |
1994年 | 75篇 |
1993年 | 58篇 |
1992年 | 64篇 |
1991年 | 41篇 |
1990年 | 30篇 |
1989年 | 33篇 |
1988年 | 29篇 |
1987年 | 31篇 |
1986年 | 24篇 |
1985年 | 21篇 |
1984年 | 23篇 |
1983年 | 27篇 |
1982年 | 16篇 |
1981年 | 21篇 |
1980年 | 16篇 |
1979年 | 10篇 |
1978年 | 12篇 |
1977年 | 12篇 |
1976年 | 7篇 |
1971年 | 6篇 |
1969年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
991.
Suita S Tajiri T Kaneko M Hirai M Mugishima H Sugimoto T Tsuchida Y 《Journal of pediatric surgery》2007,42(3):489-493
Background/Purpose
This study aims to clarify the implications of MYCN amplification in patients with high-risk neuroblastomas treated with 2 different regimens of induction chemotherapy established by the Japan Study Group for Advanced Neuroblastoma.Methods
Between 1985 and 2003 in Japan, 392 patients with stage 4 neuroblastomas who were older than 12 months were treated with 2 regimens of induction chemotherapy (the combination of cyclophosphamide [CTX], cisplatin [CDDP], pirarubicin, and vincristine or etoposide). Regimen 91A3 or 98A3 (A3) (CTX 2400 mg/m2, CDDP 125 mg/m2) was a higher dose combination of CTX and CDDP than regimen 85A1 or 91A1 (A1) (CTX 1200 mg/m2, CDDP 90 mg/m2). The 392 cases were classified into 3 groups (A, 1 copy; B, 2-9 copies; C, more than 10 copies) based on the MYCN amplification status by a Southern blot analysis.Results
The 5-year overall survival rate (5-YS) was 41.1% for all 392 cases. Regarding the MYCN amplification status, the 5-YS was 46.6% for A group (n = 227), 22.7% for B group (n = 26), and 36.0% for C group (n = 139). A flouresence in situ hybridization analysis showed the presence of the cells with more than 10 copies in cases with 2 to 9 copies based on the Southern blot findings. Of the 227 patients in a group, the 5-YS was 46.7% for the 70 cases treated by A3 and 47.0% for 154 cases treated by A1 (nonsignificant). The 5-YS of the 210 patients with stem cell transplantation (SCT) (51.%) was significantly better than that of the 127 patients without SCT (41.1%) (P < .05).Conclusions
Regarding the MYCN amplification status, the tumor aggressiveness might thus be different between 2 and 9 copies and a single copy of MYCN. In neuroblastomas with 2 and 9 copies of MYCN based on a Southern blot analysis, the MYCN amplification status should be analyzed using the flouresence in situ hybridization method. Induction chemotherapy followed by SCT according to the Japan Study Group for Advanced Neuroblastoma protocol improved the outcome of neuroblastomas with MYCN amplification; however, obtaining a further improvement in the long-term survival of stage 4 neuroblastomas may therefore require the development of an even more effective treatment modality. 相似文献992.
993.
994.
995.
996.
Naoe M Ogawa Y Hasebe Y Morita J Shichijo T Igarashi A Fuji K Iwamoto S Suzuki T Terao S 《Oncology research》2011,19(10-11):479-486
Metastatic renal cell carcinoma (mRCC) treatment consists of molecular targeted agents and cytokines that have fundamentally different mechanisms of action. Clinical responses also differ; complete response is rare with molecular targeted agents but is sometimes achieved with cytokine therapies. Because of the relatively high efficacy of combination therapy with low-dose interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) against mRCC, it is important to reevaluate cytokine therapies in vitro. Here, we show that when IL-2 is administered in combination with IFN-alpha, a stronger cytotoxic effect of PBMCs on RCC cell lines is observed than when IL-2 is administered alone. The upregulation of TNF-related apoptosis-inducing ligand on NK cell by IL-2 and suppression of regulatory T cells (Tregs) by IFN-alpha were recognized at the same time when cytotoxicity of peripheral blood mononuclear cells (PBMCs) was enhanced. IL-2 is known to activate natural killer cell cytotoxicity; however, IL-2 also stimulates Treg expansion, which enhances immunosuppression. On the other hand, IFN-alpha negatively regulates Treg cells, thereby increasing the function of immune effector cells. Our in vitro results may explain, at least in part, the clinical efficacy of combination low-dose IL-2 and IFN-alpha therapy against mRCC. 相似文献
997.
Nishimura M Ejiri Y Kishimoto S Suzuki S Satoh T Horie T Narimatsu S Naito S 《Drug metabolism and pharmacokinetics》2011,26(2):137-144
We evaluated a novel three-dimensional primary culture system using micro-space plates to determine the expression levels of 61 target (drug-metabolizing enzymes, transporters, and nuclear receptors) mRNAs in human hepatocytes. We measured mRNA expression levels of many target genes in four lots of cryopreserved human hepatocyte primary cells after 120 h of culture and compared differences in mRNA expression levels between cultures using traditional plates and those using micro-space plates. In this study, we show that the mRNA levels of many experimental targets in human hepatocytes before inoculation resemble the levels inside the human liver. Furthermore, we show that the rate of change of expression levels of many target mRNAs relative to the value before inoculation of the hepatocytes into micro-space plates was relatively smaller than the rate of change in hepatocytes inoculated into traditional plates. Pharmacokinetics-related examinations using this system are possible within a time frame of 120 h. We report that this novel three-dimensional culture system reproduces mRNA expression levels that are nearer to those in the liver in vivo and is an excellent platform for maintaining mRNA expression levels of drug-metabolizing enzymes and transporters when compared to common monolayer cultures. 相似文献
998.
Usui N Takeshita A Nakaseko C Dobashi N Fujita H Kiyoi H Kobayashi Y Sakura T Yahagi Y Shigeno K Ohwada C Miyazaki Y Ohtake S Miyawaki S Naoe T Ohnishi K;Japan Adult Leukemia Study Group 《Cancer science》2011,102(7):1358-1365
In order to investigate better molecular-target therapy for acute myeloid leukemia (AML), we conducted a phase I trial of a combination of gemtuzumab ozogamicin (GO) with conventional chemotherapy. Between January 2007 and December 2009, a total of 19 adult Japanese patients with relapsed or refractory CD33-positive AML (excluding acute promyelocytic leukemia) were enrolled. All registered patients received a standard dose of cytarabine (Ara-C) (100 mg/m(2) × 7 days), combined with either idarubicin (IDR) (10-12 mg/m(2) × 3 days) or daunorubicin (DNR) (50 mg/m(2) × 3-5 days), and then GO (3-5 mg/m(2) ), which was administered 1 day after the last infusion of IDR (IAG regimen) or DNR (DAG regimen). While doses of both GO and IDR and the administration period of only DNR were increased, the dose-limiting toxicity (DLT) was assessed. Among 19 patients (nine in the IAG regimen, 10 in the DAG regimen), the median age was 59 years (range 33-64), and the relapsed/refractory ratio was 13/6. In the therapy using 3 mg/m(2) GO in the IAG or DAG regimen, grade 3/4 leukopenia and neutropenia were observed in all patients, but none had grade 3/4 non-hematological toxicities, except febrile neutropenia. Three patients in the IAG regimen who were administered 5 mg/m(2) GO showed DLT. No patients had veno-occlusive disease or sinusoidal obstructive syndrome. In conclusion, 3 mg/m(2) GO combined with Ara-C and IDR or DNR can be safely administered, and phase II trials should be conducted to investigate the clinical efficacy of the combination therapy. 相似文献
999.
Torisu R Suzuki SO Masui K Yoshimoto K Mizoguchi M Hashizume M Canoll P Goldman JE Sasaki T Iwaki T 《Brain tumor pathology》2011,28(1):33-42
We previously reported that retrovirally transduced platelet-derived growth factor-B (PDGFB) in glial progenitors of the rat
cerebral white matter, subventricular zone, or brain stem induced malignant brain tumors closely resembling human glioblastoma
(GBM). While human GBMs may progress over the period of several months to a few years, prospective, long-term in-vivo observation
of histological changes of the tumor tissues is not feasible in these models, because the animals undergo rapid tumor progression
and mortality within approximately 1 month. We thus performed successive, long-term in-vivo transplantation of the PDGFB-induced
tumor cells into the rat cerebrum. Primary retroviral transduction of PDGFB in the glial progenitors of the rat basal ganglia
induced malignant glioma resembling human GBM or anaplastic oligodendroglioma (AOL) consisting of relatively monomorphous
tumor cells expressing markers for the oligodendrocyte lineage. In the course of long-term successive transplantation, tumor
cells presented pleomorphism as well as focal GFAP expression. This suggests that secondary chromosomal aberration and dysregulation
of gene expression following accelerated cell cycle by PDGFB stimulation would induce morphological and immunophenotypic changes
in tumor cells. Furthermore, while the primary tumors contained only a minor fraction of proviral GFP-expressing or hemagglutinin-expressing
cells, most tumor cells came to express these proviral genes in the course of serial transplantation suggesting a persistent
role of PDGFB-expressing cells in maintenance and growth of the tumors. This model would be useful for investigation of the
long-term effects of PDGFB stimulation in glioma tissues on anaplastic evolution. 相似文献
1000.
Zennami K Yoshikawa K Kondo E Nakamura K Upsilonamada Y De Velasco MA Tanaka M Uemura H Shimazui T Akaza H Saga S Ueda R Honda N 《Oncology reports》2011,26(2):327-333
Molecular targeting agents have become formidable anticancer weapons showing much promise against refractory tumors and functional peptides and are among the more desirable of these nanobio-tools. Intracellular delivery of multiple functional peptides forms the basis for a potent, non-invasive mode of delivery, providing distinctive therapeutic advantages. We examine the growth suppression efficiency of human renal cell carcinoma (RCC) by single-peptide targeting. We simultaneously introduced p16INK4a tumor suppressor peptides by Wr-T-mediated peptide delivery. Wr-T-mediated transport of p16INK4a functional peptide into 10 RCC lines, lacking expression of the p16INK4a molecule, reversed the specific loss of p16 function, thereby drastically inhibiting tumor growth in all but 3 lines by >95% within the first 96?h. In?vivo analysis using SK-RC-7 RCC xenografts in nude mice demonstrated tumor growth inhibition by the p16INK4a peptide alone, however, inoculation of Wr-T and the p16INK4a functional peptide mixture, via the heart resulted in complete tumor regression. Thus, restoration of tumor suppressor function with Wr-T peptide delivery represents a powerful approach, with mechanistic implications for the development of efficacious molecular targeting therapeutics against intractable RCC. 相似文献